
- Ben Goldacre takes our corporate overlords to task.
- Top-line results of AstraZeneca's Phase III Plato study in acute coronary syndrome show its Brilinta (ticagrelor) is better than BMS/Sanofi's Plavix at preventing cardiovascular events. Full data will be presented in August at the European Society of Cardiology meeting.
- Eisai to Pfizer: we have the right to terminate our aricept alliance (B'berg)
- Is a major, industry-backed, announcement on Health Care Reform coming today? The deal to save over $2 trillion in the next decade will be trumpeted today, says the Washington Post.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.